FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224324897> ?p ?o ?g. }

• W4224324897 endingPage "907" @default.
• W4224324897 startingPage "902" @default.
• W4224324897 abstract "There is a growing use of ticagrelor in patients undergoing neuroendovascular procedures, especially those who demonstrate clopidogrel resistance. While multiple dosages are studied in the cardiology literature, the optimal dose for patients with neurological pathology has yet to be established. Here, we describe a single center experience involving 39 patients who underwent neuroendovascular procedures that then received an adjusted lower dose of ticagrelor.A retrospective chart review was performed between 2013 and 2017 for patients on dual anti-platelet therapy (DAPT) for either cervical or intracranial vascular pathologies, as well as stenting of the neurovasculature, including carotid arteries. Patients were placed on ticagrelor if their measured P2Y12 reaction units (PRU) responses to clopidogrel were outside the expected range in our center using the VerifyNow™ P2Y12 test. All patients were maintained on a dose of 45 mg twice daily except for one patient who received 22.5 mg twice daily. Responsiveness to ticagrelor were measured utilizing the VerifyNow™ P2Y12 test.The mean number of days for follow-up post treatment initiation was 532 days. A total of 39 patients were included in the analysis. Of these, 8 patients (21%) received implantation of intracranial stents (5 patients received pipeline embolization devices, 1 patient received stent-assisted coiling, and 2 patients received intracranial stents for atherosclerotic disease). Fourteen patients (35%) received carotid angioplasty and stenting. Seventeen patients (44%) did not receive permanent implantation of a stent. All patients on the lower dose ticagrelor of 45 mg twice daily achieved responsiveness (i.e., PRU < 194). Hemorrhagic transformation of ischemic stroke occurred in one patient (2.5%). No other hemorrhagic complications were encountered. No thromboembolic events were recorded aside from one patient (2.5%) with intracranial atherosclerotic disease who had an ischemic event.A lower dose of ticagrelor (45 mg twice daily) appears to be safe and effective in this small cohort of patients who are resistant to clopidogrel per P2Y12 testing and who have increased risk of ischemic or hemorrhagic strokes due to neurovascular pathologies and implants. Further randomized studies are required to confirm these findings." @default.
• W4224324897 created "2022-04-26" @default.
• W4224324897 creator A5006267379 @default.
• W4224324897 creator A5013791930 @default.
• W4224324897 creator A5029371485 @default.
• W4224324897 creator A5062049081 @default.
• W4224324897 creator A5073240615 @default.
• W4224324897 creator A5088497358 @default.
• W4224324897 creator A5089170788 @default.
• W4224324897 date "2022-04-24" @default.
• W4224324897 modified "2023-10-12" @default.
• W4224324897 title "An alternative reduced dose regimen of ticagrelor for neuroendovascular patients" @default.
• W4224324897 cites W175512219 @default.
• W4224324897 cites W1977457877 @default.
• W4224324897 cites W2005993749 @default.
• W4224324897 cites W2028732571 @default.
• W4224324897 cites W2071520634 @default.
• W4224324897 cites W2101924617 @default.
• W4224324897 cites W2126493359 @default.
• W4224324897 cites W2141358924 @default.
• W4224324897 cites W2154988164 @default.
• W4224324897 cites W2295055355 @default.
• W4224324897 cites W2361921955 @default.
• W4224324897 cites W2514376554 @default.
• W4224324897 cites W2607393466 @default.
• W4224324897 cites W2726342676 @default.
• W4224324897 cites W2761757035 @default.
• W4224324897 cites W2785279414 @default.
• W4224324897 cites W2911613746 @default.
• W4224324897 cites W3016558077 @default.
• W4224324897 cites W3025672389 @default.
• W4224324897 cites W3032853759 @default.
• W4224324897 cites W3043492355 @default.
• W4224324897 doi "https://doi.org/10.1177/17085381221092858" @default.
• W4224324897 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35466828" @default.
• W4224324897 hasPublicationYear "2022" @default.
• W4224324897 type Work @default.
• W4224324897 citedByCount "0" @default.
• W4224324897 crossrefType "journal-article" @default.
• W4224324897 hasAuthorship W4224324897A5006267379 @default.
• W4224324897 hasAuthorship W4224324897A5013791930 @default.
• W4224324897 hasAuthorship W4224324897A5029371485 @default.
• W4224324897 hasAuthorship W4224324897A5062049081 @default.
• W4224324897 hasAuthorship W4224324897A5073240615 @default.
• W4224324897 hasAuthorship W4224324897A5088497358 @default.
• W4224324897 hasAuthorship W4224324897A5089170788 @default.
• W4224324897 hasConcept C126322002 @default.
• W4224324897 hasConcept C127413603 @default.
• W4224324897 hasConcept C141071460 @default.
• W4224324897 hasConcept C2777628954 @default.
• W4224324897 hasConcept C2777849778 @default.
• W4224324897 hasConcept C2778583881 @default.
• W4224324897 hasConcept C2779169563 @default.
• W4224324897 hasConcept C2780073493 @default.
• W4224324897 hasConcept C2780645631 @default.
• W4224324897 hasConcept C2780890252 @default.
• W4224324897 hasConcept C2781068581 @default.
• W4224324897 hasConcept C2781413609 @default.
• W4224324897 hasConcept C2987047532 @default.
• W4224324897 hasConcept C49059817 @default.
• W4224324897 hasConcept C71924100 @default.
• W4224324897 hasConcept C78519656 @default.
• W4224324897 hasConceptScore W4224324897C126322002 @default.
• W4224324897 hasConceptScore W4224324897C127413603 @default.
• W4224324897 hasConceptScore W4224324897C141071460 @default.
• W4224324897 hasConceptScore W4224324897C2777628954 @default.
• W4224324897 hasConceptScore W4224324897C2777849778 @default.
• W4224324897 hasConceptScore W4224324897C2778583881 @default.
• W4224324897 hasConceptScore W4224324897C2779169563 @default.
• W4224324897 hasConceptScore W4224324897C2780073493 @default.
• W4224324897 hasConceptScore W4224324897C2780645631 @default.
• W4224324897 hasConceptScore W4224324897C2780890252 @default.
• W4224324897 hasConceptScore W4224324897C2781068581 @default.
• W4224324897 hasConceptScore W4224324897C2781413609 @default.
• W4224324897 hasConceptScore W4224324897C2987047532 @default.
• W4224324897 hasConceptScore W4224324897C49059817 @default.
• W4224324897 hasConceptScore W4224324897C71924100 @default.
• W4224324897 hasConceptScore W4224324897C78519656 @default.
• W4224324897 hasIssue "5" @default.
• W4224324897 hasLocation W42243248971 @default.
• W4224324897 hasLocation W42243248972 @default.
• W4224324897 hasOpenAccess W4224324897 @default.
• W4224324897 hasPrimaryLocation W42243248971 @default.
• W4224324897 hasRelatedWork W175512219 @default.
• W4224324897 hasRelatedWork W2013173130 @default.
• W4224324897 hasRelatedWork W2015641383 @default.
• W4224324897 hasRelatedWork W2066953453 @default.
• W4224324897 hasRelatedWork W2096379851 @default.
• W4224324897 hasRelatedWork W2167341647 @default.
• W4224324897 hasRelatedWork W2318608459 @default.
• W4224324897 hasRelatedWork W4205250762 @default.
• W4224324897 hasRelatedWork W4205858089 @default.
• W4224324897 hasRelatedWork W4385476740 @default.
• W4224324897 hasVolume "31" @default.
• W4224324897 isParatext "false" @default.
• W4224324897 isRetracted "false" @default.
• W4224324897 workType "article" @default.